How This Evidence Evolved
Liquid Biopsy Maturation
From circulating tumor DNA concept to minimal residual disease detection and multi-cancer screening
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Recurrence-free survival (non-inferiority of ctDNA-guided approach)
Stage III/IV cancer incidence at 3–4 years
ctDNA-guided escalation and de-escalation of adjuvant therapy
Recurrence-free survival at three years for ctDNA-negative and two years for ctDNA-positive patients
Cancer signal sensitivity, specificity and origin prediction accuracy
Integration into clinical practice guidelines and recommendations
Validated sensitive ctDNA assays can guide advanced-cancer therapy, subject to assay limits; tissue is preferred for many. MRD-directed treatment is not recommended routinely.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Circulating mutant DNA to assess tumor dynamics
ctDNA measurement to monitor tumor dynamics during colorectal-cancer therapy
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Biomarker detection and clinical outcomes
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Driver/resistance mutation distribution and frequency
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Recurrence-free survival (non-inferiority of ctDNA-guided approach)
Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial.
Stage III/IV cancer incidence at 3–4 years
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
ctDNA-guided escalation and de-escalation of adjuvant therapy
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.
Recurrence-free survival at three years for ctDNA-negative and two years for ctDNA-positive patients
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Cancer signal sensitivity, specificity and origin prediction accuracy
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.